IDH2 and non-small cell lung carcinoma: To determine whether IDH‐mutant NSCLC patients could benefit from the combination of IDH inhibitors and EGFR TKIs, we overexpressed wild‐type or mutant (IDH1‐R132H) IDH1 in HCC827 cells carrying an EGFR mutation in vitro.